BioHarvest Sciences Inc. Achieves Critical Milestones in the BioFarming of Cannabis


Ryan Allway

June 8th, 2021

News


Staying on course for the commercialization of Cannabis & Hemp Products in the first half of 2022

 

Vancouver, BC / June 8, 2021, / BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) announces today that it has successfully performed certain critical tasks necessary for the completion of its Cannabis development program. The Company has been adapting its unique and proprietary BioFarming technology, which enables the production of cannabinoids without growing the cannabis plant itself. Despite the many challenges caused by the Covid 19 pandemic, the Company’s dedicated R&D team has stayed the course in its quest to bring to the world Cannabis-based products that will be leading edge in quality, consistency, and cleanliness at a uniquely competitive cost.  BioHarvest expects to commercialize its first Cannabis-based products in the first half of 2022.

 

Throughout the development program, the Company has communicated multiple important milestones that not only demonstrate the feasibility of using BioHarvest’s proprietary BioFarming technology for the production of Cannabis, but also the unique capabilities and knowledge of its R&D team. No other company has been able to grow Cannabis trichomes in liquid media. While other academic institutions have spent significant time and resources in this endeavor, none have been able to accomplish this major milestone, which is critical for utilizing biotech processes to produce Cannabis at industrial scale.

 

In February 2021, BioHarvest announced its unique scientific ability to optimize the production of trichomes in liquid media. This is critical as the trichome is the micro-factory that produces cannabinoids, flavonoids, and terpenes.

 

Over the course of the last three months, the Company has achieved a number of significant milestones including:

 

  1. Measurement Methods – BioHarvest has developed the required baseline scientific measurement methods to be able to evaluate the level of cannabinoids in its unique composition of cells with trichomes. There is no known industry standard in this regard, and given that BioHarvest’s contribution is both novel and pioneering in this specific field, it has had to develop its own measurement methods. This requires significant knowledge and expertise that are unique to BioHarvest. The Company will utilize this knowledge throughout the development process, to measure the cannabinoid levels in the trichomes and the overall cell biomass.

 

  • Nature of Trichomes – BioHarvest has been able to develop a unique configuration of cells with trichomes which it calls “Bio-Tricho-Bubbles” (Figure 1:) which is similar in appearance to what is called Ice Hash or Bubble Hash. Ice Hash/ Bubble Hash results from the mechanical separation of glandular trichome heads from raw Cannabis flowers (Figure 2:). BioHarvest’s “Bio-Tricho-Bubbles” are similar in shape to Ice Hash/Bubble Hash but do not require a major mechanical process to separate out the glandular trichome heads from raw Cannabis flowers. BioHarvest’s “Bio-Tricho-Bubbles” feature trichomes at a higher density than that of regular trichomes on a Cannabis plant (Figure 3:).

 

  • Bioreactors – In parallel with continuing the commercialization process, and with its newly developed measurement methods, the R&D team is heavily focused on optimizing the cannabinoid levels in their unique “Bio-Tricho-Bubbles”. For that purpose, a significant quantity of dedicated bioreactors (Figure 4:) are already in use producing cannabinoids. This is currently the highest priority of the R&D team where it will be applying its more than 50 people-years of cumulative experience of plant cell growth.

 

  • Drying – Due to the unique “Bio-Tricho-Bubbles” composition of the BioHarvest cells with trichomes, the Company has commenced optimizing the drying process of these unique “Bio-Tricho-Bubbles” to minimize any potential damage to the trichome during the drying process.

 

We continue to make steady progress towards achieving our goals in the Cannabis vertical of the Company,” said Ilan Sobel, CEO of BioHarvest, and added “We keep making history with our scientific and technological achievements in the area of plant-based cell growth. We try to communicate such achievements as frequently as possible, so as to reinforce the confidence of our shareholders. We understand the desire of the investment community to have such updates and we are consistently trying to maintain a balance between information disclosure and potential competitive impact. I am celebrating today my first anniversary at BioHarvest, and I have full confidence in our team to deliver on the goals we have set”.

 

Yochi Hagay, CTO of BioHarvest, commented: “I am very proud of the achievements of my team. Despite all the hardship caused by the pandemic, which not only limited our capability to conduct proper work in the labs, but also restricted the availability of critical materials, the team was able to make the significant achievements described above. Plant biology is a complicated universe, but we have been consistently capable of navigating our way and delivering the required results. Obviously, biological research requires time, and we are not sparing any efforts to complete our tasks on time. I remain optimistic not only in demonstrating the feasibility of BioFarming Cannabis but also in the commercial production of cannabinoids based on our proprietary and patented plant cell growth technology”.

 

Eitan Popper, former President & Co-Founder of MedReleaf, and current Chairman of BioHarvest’s Advisory Board added: “The progress that BioHarvest’s R&D team has made with Cannabis cells and Cannabis trichomes in particular, is both disruptive from an industry perspective and ground-breaking from a scientific point of view. Full scale-up and commercialization, appear to be closer than ever.”

 

The Company is hosting a shareholder update conference via Zoom on July 8th at 2 PM Eastern Time where the achievements noted above will be discussed further. Register Now!

 

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to also become a leading supplier of cannabis for both medicinal and legal recreational purposes.

For more information visit: www.bioharvest.com.

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: [email protected]

 

Forward-Looking Statements 

Information set forth in this news release includes might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance we will be able to commercialize our first Cannabis products in the first half of 2022. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. The success of the Company in demonstrating its ability to consistently grow in solution trichomes from multiple plant strains is not an assurance that the Company will be able to commence commercial production when anticipated or at all. While the company is in the process of constructing a two-ton production facility the Company’s current licensing only permits scientific research. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading